Image credit: Peterschreiber.media | stock.adobe.com

Results from the Phase III EMPACT-MI trial showed that compared with placebo, patients receiving Jardiance (empagliflozin, Boehringer Ingelheim and Eli Lilly and Company) had significantly lower rates of treatment up to their first hospitalization for heart failure on the trial’s main composite This shows that a 10% reduction in relative risk, which is an evaluation item, has been achieved. (HF) or all-cause mortality did not reach statistical significance. Jardiance, a sodium glucose cotransporter 2 (SGLT2) inhibitor, has been shown to reduce the risk of cardiovascular death (CVD) or hospitalization for heart failure in chronic heart failure patients with reduced left ventricular ejection fraction . Additionally, Jardiance has been shown to reduce the risk of cardiovascular disease and heart failure hospitalization in patients with chronic heart failure who have preserved left ventricular ejection fraction.²

“These results further expand our understanding of SGLT2 inhibitors and demonstrate the potential for Jardiance to impact key outcomes in a broad population of adults with heart failure, chronic kidney disease, or type 2 diabetes. It contributes to a body of evidence across six clinical studies examining sex,” said Mohamed. “We are thrilled to be partnering with Boehringer Ingelheim Pharmaceuticals to develop this new drug,” said Eid, MD, MS, MD, vice president of clinical development and medical affairs for Cardiac, Renal, and Metabolic Medicine at Boehringer Ingelheim Pharmaceuticals, in a press release. “Building on this strong foundation, we continue to raise awareness, generate real-world evidence, and advance treatments for people affected by relevant cardiovascular, renal, and metabolic diseases. I am committed to leading efforts to achieve this goal.”¹

Jardiance has previously been approved to reduce the risk of cardiovascular disease and hospitalization in adult patients with heart failure. To reduce the risk of further worsening of kidney disease, end-stage renal disease, CVD death, and hospitalization in adults with chronic kidney disease. Lowering the risk of CVD in adults with type 2 diabetes and known cardiovascular disease. For people with type 2 diabetes over the age of 10, combine diet and exercise to lower blood sugar levels.

In the multi-center, randomized, parallel-group, double-blind, placebo-controlled EMPACT-MI superiority trial, researchers administered 10 mg once daily alongside standard of care in more than 6,500 adult patients. Jardiance was evaluated within 14 days after administration. He is in the hospital due to a heart attack. The primary endpoint of this trial was time to first hospitalization for heart failure or all-cause death (up to 26 months). Enrollment criteria include no history of chronic heart failure, eligibility regardless of type 2 diabetes and chronic kidney disease status.

Trial data showed that patients receiving Jardiance had a 23% relative risk reduction in time to first hospitalization for heart failure and a 33% relative risk reduction in total length of hospital stay for heart failure compared to placebo. I did.

“Despite significant advances in treatment, heart attacks remain the most common cause of heart failure,” Jeff Emick, M.D., Lilly’s senior vice president of product development, said in a press release. “Needs remain unmet.” Despite the risk of developing new heart failure and other common complications after a heart attack, Jardiance is an important treatment for adults with chronic heart failure that reduces the risk of cardiovascular death and heart failure hospitalization. proven and serves the needs of millions of people around the world. ”¹

References

1. Results from the EMPACT-MI Phase III trial investigating the effect of Jardiance® (empagliflozin) on the risk of heart failure hospitalization and death in adults after a heart attack are announced. Eli Lilly. news release. April 6, 2024. Accessed April 8, 2024. https://investor.lilly.com/news-releases/news-release-details/results-announced-impact-mi-phase-iii-trial-investigation-effect

2. Kosiborod MN, Ungerman CE, Collins SP, et al. Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized with acute heart failure – results from the EMPULSE trial. Circulation. Published online on April 4, 2022. Accessed April 8, 2024. doi:10.1161/ CIRCULATIONAHA.122.059725